Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Nonrandomized, Open-Label Investigation of Subcutaneous Ramucirumab Administration in Participants With Advanced Solid Tumors

NCT04557384 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT04557384
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04557384 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Nonrandomized, Open-Label Investigation of Subcutaneous Ramucirumab Administration in Participants With Advanced Solid Tumors
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Terminated
Start date
February 23, 2021
Completion date
May 25, 2021
Enrollment
3 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor